

16 24 #7  
5/1/01  
8W  
CASE MA-81

RECEIVED  
APR 17 2001

TECH CENTER 1800/2900

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Samuel J. DuBoff  
Type or print name

*Samuel J. DuBoff*  
Signature

April 12, 2001  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

DUBOWCHIK ET AL.

APPLICATION NO: 09/717,563 ✓

FILED: NOVEMBER 21, 2000 ✓

FOR: NEUROTROPHIC BICYCLIC DIAMIDES ✓

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(203) 677-7787

  
\_\_\_\_\_  
Samuel J. DuBoff  
Attorney for Applicants  
Reg. No. 25,969

Date: 2/12/07  
Customer No. 23914

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000Sheet 1 of 3  
**RECEIVED**  
APR 17 2001  
TECH CENTER 1600/2900  
Group -

#7

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,622,970	4/22/97	D. Armistead, et al			
	AB	5,330,993	7/19/94	D. Armistead, et al			
	AC	5,192,773	3/9/93	D. Armistead, et al			
	AD	5,516,797	5/14/96	D. Armistead, et al			
	AE	5,696,135	12/9/97	J. P. Steiner, et al			
	AF	5,721,256	2/24/98	G. S. Hamilton, et al			
	AG	5,654,332	8/5/97	D. Armistead			
	AH	5,780,484	7/14/98	R. E. Zelle, et al			
	AI	5,786,378	7/28/98	G. S. Hamilton, et al			
	AJ	5,795,908	8/18/98	G. S. Hamilton, et al			
	AK	5,798,355	8/25/98	J. P. Steiner, et al			
	AL	5,801,187	9/1/98	Jia-He Li, et al			
	AM	5,801,197	9/1/98	J. P. Steiner, et al			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AN	WO 94/07858	4/14/94	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 92/19593	11/12/92	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 92/21313	12/10/92	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 564924B1	10/13/93	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AR	EP 405994A2	1/2/91	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AS	WO 96/40140	12/19/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AT	WO 96/40633	12/19/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AU	WO 97/16190	5/9/97	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AV	WO 96/41609	12/27/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AW	WO 97/36869	10/9/97	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AX	WO 98/13343	4/2/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AY	WO 98/13355	4/2/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000

Group -



(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AZ	WO 98/20891	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BA	WO 98/20892	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 98/20893	5/22/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BC	WO 98/29116	7/9/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 98/29117	7/9/98	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 99/10340	3/4/99	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 99/21552	5/6/99	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BG	A. Ruhlmann, et al, "Effects of the Immunosuppressive Drugs CsA and FK506 on Intracellular Signalling and Gene Regulation," IMMUNOBIOLOGY, <b>198</b> , pp. 192-206, 1997
BH	S. L. Schreiber, et al, "Molecular Recognition of Immunophilins and Immunophilin-Ligand Complexes," TETRAHEDRON, <b>48</b> (13), pp. 2545-2558, 1992
BI	T. Wang, et al, "Specific Interaction of Type I Receptors of the TGF- $\beta$ Family with the Immunophilin FKBP-12," SCIENCE, <b>265</b> , pp. 674-676, 1994
BJ	A. M. Cameron, et al, "FKBP12 Binds the Inositol 1,4,5-Trisphosphate Receptor at Leucine-Proline (1400-1401) and Anchors Calcineurin to This FK506-Like Domain," J. BIOLOGICAL CHEMISTRY, <b>272</b> (44), pp. 27582-27588, 1997
BK	T. Wang, et al, "The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGF $\beta$ Family Type I Receptors," CELL, <b>86</b> , pp. 435-444, 1996
BL	D. S. Yamashita, et al, "Design, Synthesis and Evaluation of Dual Domain FKBP Ligands," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, <b>4</b> (2), pp. 325-328, 1994
BM	D. M. Armistead, et al, "Design, Synthesis and Structure of Non-Macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506," ACTA CRYST., <b>D51</b> , pp. 522-528, 1995
BN	W. E. Lyons, et al, "Immunosuppressant FK506 Promotes Neurite Outgrowth in Cultures of PC12 Cells and Sensory Ganglia," PROC. NATL. ACAD. SCI. USA, <b>91</b> , pp. 3191-3195, 1994
BO	B. G. Gold, et al, "The Immunosuppressant FK506 Increases the Rate of Axonal Regeneration in Rat Sciatic Nerve," J NEUROSCIENCE, <b>15</b> (11), pp. 7509-7516, 1995
BP	G. S. Hamilton, et al, "Neuroimmunophilin Ligands as Novel Therapeutics for the Treatment of Degenerative Disorders of the Nervous System," CURRENT PHARMACEUTICAL DESIGN, <b>3</b> , pp. 405-428, 1997

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 3 of 3

ATTY. DOCKET NO.  
MA-81  
APPLICATION NO.  
09/717,563  
APPLICANT  
DUBOWCHIK ET AL.  
FILING DATE  
NOVEMBER 21, 2000

**RECEIVED**  
APR 17 2001  
TECH CENTER 1600/2900



**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

BQ	B. S. Gold, et al, "A Nonimmunosuppressant FKBP-12 Ligand Increases Nerve Regeneration," EXPERIMENTAL NEUROLOGY, <b>147</b> , pp. 269-278, 1997
BR	S. H. Snyder, et al, "Immunophilins and the Nervous System," NATURE MEDICINE, <b>1</b> (1), pp. 32-37, 1995
BS	B. G. Gold, et al, "The Immunosuppressant FK506 Increases GAP-43 mRNA Levels in Axotomized Sensory Neurons," NEUROSCIENCE LETTERS, <b>241</b> , pp. 25-28, 1998
BT	B. G. Gold, et al, "Immunophilin FK506-Binding Protein 52 (Not FK506-Binding Protein 12) Mediates the Neurotrophic Action of FK506," JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, <b>289</b> (3), pp. 1202-1210, 1999
BU	C. T. Craescu, et al, "Three-Dimensional Structure of the Immunophilin-Like Domain of FKBP59 in Solution," BIOCHEMISTRY, <b>35</b> , pp. 11045-11052, 1996
BV	J. R. Hauske, et al, "Investigation of the Effects of Synthetic, Non-Cytotoxic Immunophilin Inhibitors on MDR, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, <b>4</b> (17), pp. 2097-2102, 1994
BW	M. M. Endrich, et al, "The V3 Loop of Human Immunodeficiency Virus Type-1 Envelope Protein is a High-Affinity Ligand for Immunophilins Present in Human Blood," EUR. J. BIOCHEM., <b>252</b> , pp. 441-446, 1998
BX	A. Karpas, et al, "Inhibition of Human Immunodeficiency Virus and Growth of Infected T Cells by the Immunosuppressive Drugs Cyclosporin A and FK 506." PROC. NATL. ACAD. SCI. USA, <b>89</b> , pp. 8351-8355, 1992

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.